Articles tagged with Lung Cancer
A special issue of the Journal of the American College of Radiology addresses imaging-based screening and radiology's role in preventive medicine. The issue explores breast density legislation, digital breast tomosynthesis, lung cancer screening, and CT colonography reimbursement, highlighting both benefits and controversies.
A University of Colorado Cancer Center study found that crizotinib treatment reduces kidney function in ALK positive non-small cell lung cancer patients. Kidney function recovered after treatment, but additional tests are recommended if concerns arise.
Researchers at UCSF have developed a new strategy to block the mutated ras protein, which drives three out of ten cancers, including lung and colon cancers. The small molecules efficiently kill ras-driven cancer cells in human lung cancer cell cultures.
Researchers found that inhibiting ion channel TRPC5 limits kidney filtration loss after injury, suggesting a new therapeutic target. The study demonstrates the protective effects of TRPC5 inhibition on kidney function and provides hope for treating kidney failure.
Researchers identified KDM2A as a histone demethylase associated with non-small cell lung cancer. Induced KDM2A expression increased cell proliferation and invasiveness through ERK1/2 signaling pathway activation.
A Phase 1B study of MK-3475, an anti-PD-1 immunotherapy drug, showed encouraging results in treating non-small cell lung cancer, with a 24% response rate and median overall survival of 51 weeks. The drug, developed by Merck, allows the immune system to detect and attack cancer cells.
Glen J. Weiss, MD, presents studies on TSR-011, a potent ALK and TRK inhibitor, and Ki67, a measure of cell proliferation, in non-small cell lung cancer (NSCLC) tumors collected before chemotherapy and after surgery. These studies show preliminary clinical activity against various tumor types.
The Cell-CT platform detected lung cancer in patient sputum samples with a sensitivity of over 95% and specificity of 99.8%. The technology creates comprehensive 3D digital images of cells, making it possible to determine the presence or absence of cancer with great accuracy.
Dr. Avrum Spira has received the Alton Ochsner Award for his seminal research contributions to understanding the biological response of lung tissue to tobacco smoke. His work has led to the development of early detection biomarkers for lung cancer and molecular biomarkers for COPD treatment guidance.
Researchers developed a breath-based test to detect lung cancer using a colorimetric sensor array that detects unique chemical signatures. The test accurately distinguished breath samples from people with lung cancer from controls.
A study at Dana-Farber Cancer Institute discovered a gene fusion that fuels the growth of some lung adenocarcinomas, making targeted therapies effective for patients with specific genetic changes. The finding suggests that drugs targeting NTRK1's protein product could be effective in treating these patients.
Researchers at Boston University School of Medicine have discovered a regulatory molecule, miR-4423, that is less abundant in people with lung cancer and inhibits lung cancer cell growth. This molecule may aid in diagnosing lung cancer in earlier stages and treating the disease when at healthy levels.
Researchers at Penn Medicine found that focusing on factors like hope, randomization, and altruism can increase patient willingness to participate in clinical trials for malignant pleural mesothelioma. The study showed a significant increase in participation rates when physicians spent more time discussing these factors with patients.
Researchers found metformin as an effective radiosensitizer for treating stage III non-small cell lung cancer, improving local control and overall survival. The study suggests combining metformin with chemotherapy and radiation therapy may be a promising treatment approach.
As people age, gene mutations and epigenetic changes accumulate, increasing cancer risk. Researchers will examine the role of epigenetics in lung cancer development, seeking new biomarkers to predict cancer risk.
PF-06463922, a new investigational drug, has shown potent activity against the ALK protein kinase and its mutants, including those resistant to crizotinib. This offers a potential treatment option for patients with lung cancer harboring ALK gene abnormalities.
Researchers discovered 127 genes that appear to drive the development of a range of tumors in the body across 12 major cancer types. The study found common links among genes in different cancers, as well as mutations exclusive to particular cancer types.
The International Association for the Study of Lung Cancer (IASLC) awarded five people Advocacy Travel Awards to support their attendance at the 2013 World Conference on Lung Cancer in Sydney. The awards provide conference registration, accommodations, a free IASLC Membership, and a travel stipend.
A study suggests that Indi's blood test can accurately distinguish between benign lung nodules and early-stage lung cancer by detecting a specific combination of proteins in the blood. The test, powered by advanced protein detection technology, has a 90% accuracy rate and could complement current clinical risk factors.
PET scans can identify patients with more aggressive tumors, enabling intensified treatment for locally advanced lung cancer. The study found a strong correlation between radiation dose intensity and local control of the cancer.
A phase I clinical trial has shown that an anti-PD-L1 monoclonal antibody can produce striking responses in non-small cell lung cancer patients with metastatic disease who have failed to respond to previous chemotherapy. Smokers and former smokers are more likely to benefit from this treatment.
Researchers at Ohio State University have discovered that high levels of microRNA-31 in primary tumor cells predict lymph node metastasis and poor survival in patients with non-small cell lung cancer. Low expression levels were associated with excellent survival.
The study found a significantly lower quality of life in patients who received high-dose radiation therapy (74 Gy) compared to those receiving standard dose (60 Gy). IMRT was associated with a lower decline in QOL compared to 3-D CRT, even a year after treatment.
UT Southwestern researchers discover that a protein overactivity sabotages cellular recycling, leading to heightened cancer growth and chemotherapy resistance. Autophagy inhibition may worsen chemotherapy outcomes for patients with specific cancer mutations, according to the study published in Cell.
Researchers from RIKEN Center for Life Science Technologies identified a genetic mutation associated with improved survival rates in lung cancer patients who do not smoke. The mutation affects the NRF2 gene, which protects cells from oxidative stress.
A University of Colorado Cancer Center study found that current ALK-positive lung cancer criteria may miss patients who could benefit from crizotinib. The researchers suggest that doctors should re-evaluate borderline or atypical cases, potentially expanding treatment eligibility.
Researchers have developed a cheap and non-invasive breath test to diagnose lung cancer, which has been shown to correctly identify lung cancer patients with high sensitivity. The technique uses an electronic nose to detect volatile organic compounds in exhaled breath samples.
A new publication by the European Respiratory Society reveals that lung conditions account for 12.5% of EU deaths, with annual costs totaling at least 390 billion Euros. The White Book estimates direct and indirect costs due to lung diseases are around 400 billion Euros annually.
A prospective cohort study of 81,697 racially diverse adults found that lung cancer survival between black and white patients was similar when demographic factors and smoking were controlled. The study aimed to address racial disparities in lung cancer survival rates.
A new clinical risk calculator software has been developed to accurately classify benign and malignant spots on lung scans of smokers. The software uses a prediction model that considers several factors, including size, age, family history, and location of the nodule, to predict the probability of cancer.
A new set of evidence-based guidelines recommend lung cancer screening for high-risk populations in Ontario using low-dose computed tomography (LDCT). The guidelines suggest annual screening for two years, followed by biennial screenings until a negative result is obtained. The recommended parameters for LDCT include 120 to 140 kVp and...
Researchers recommend accelerated radiotherapy as standard treatment for un-resected non-small cell lung cancer patients not receiving concurrent chemo-radiotherapy, citing its efficiency over current practice. However, cost-effectiveness of different modified schemes remains uncertain and requires further research.
Researchers found that Notch 1 is required for initial tumor growth and survival of cancer cells. Disabling Notch 1 leads to increased cancer cell death through increased p53 stability.
A study led by UT Southwestern Medical Center researchers found that total tumor measurements greater than 3 inches predict shorter survival times in advanced lung cancer patients. Patients with larger tumors live an average of 9.5 months, compared to 12.6 months for those with smaller tumors.
Researchers at Moffitt Cancer Center identified four genetic variants associated with increased risk of death in non-small cell lung cancer patients. These variants also indicate a greater risk of death if treatment plans include surgery without chemotherapy compared to those with chemotherapy following surgery.
Researchers found that a specific pattern in tumor pathology is strongly associated with cancer recurrence. Patients with this pattern are more likely to benefit from lobectomy and have a 75% lower risk of recurrence. The study may lead to new technology to precisely identify tumors with this pattern before surgery.
Researchers at Fred Hutchinson Cancer Center are pioneering a new approach to harness the power of the adaptive immune system to control cancer. They are using high-throughput technology and large-scale data mining to identify potential immune targets and verify their immunogenicity.
Screening asymptomatic high-risk adults for lung cancer using low-dose computed tomography (LDCT) may significantly reduce mortality, according to a systematic review. The US Preventive Services Task Force reviewed 67 articles and found that LDCT screening can detect lung cancer at an earlier stage, leading to lower mortality rates.
Researchers found that obese patients initially had superior outcomes in terms of overall survival compared to normal-weight and overweight patients. However, their risk of death from any cause significantly increased once they were on the study longer than 16 months, indicating a limited time benefit of obesity in lung cancer patients.
Researchers in Canada found that funding from the pharmaceutical industry significantly decreased EGFR mutation testing after it was discontinued. The Canadian healthcare system lacked resources for implementing a national policy, leading to a substantial drop in test requests.
Researchers have identified Ephrin B2 as a promising target for treating malignant pleural mesothelioma, a rare and aggressive form of lung cancer. The study found that EPHB2 is significantly overexpressed in tumor tissue compared to normal peritoneum, suggesting its potential as a biomarker for early diagnosis and treatment.
Researchers at Moffitt Cancer Center discovered a gene expression signature that may lead to new immune therapies for lung cancer patients. High levels of NF-κB in lung cancer tumors can act as a suppressor, boosting the immune system to eliminate cancerous cells.
A study by Weill Cornell Medicine found that even healthy-looking smokers have damaged airway cells with characteristics similar to those in aggressive lung cancer. The researchers discovered that these cells express human embryonic stem cell genes, which are normally only active in developing embryos.
A European-wide study found that prolonged exposure to particulate air pollution increases the risk of lung cancer, particularly adenocarcinoma, at concentrations below EU limit values. The analysis of 17 cohort studies involved over 313,000 people and found a strong association between air pollution and lung cancer risk.
The foundation awarded six new Clinical Investigators, including Omar Abdel-Wahab and Himisha Beltran, for their cancer research programs. The recipients will receive $450,000 each, while three others received Continuation Grants worth $300,000 to support ongoing research.
Researchers have developed two new methodologies to determine ALK status in non–small-cell lung cancer (NSCLC) patients. The first method improves IHC assay sensitivity using a novel hapten and tyramide amplification, detecting low levels of ALK protein expression. The second method combines brightfield IHC with in situ hybridization f...
Researchers developed a highly accurate method to detect ALK-rearranged non-small cell lung cancer using immunocytochemistry. The study found that this method had high sensitivity and specificity, making it suitable for prescreening NSCLC patients.
Anurag Singh, PhD, has received a $100,000 ALA Lung Cancer Discovery Grant to study targeted therapies for drug-resistant lung cancers. He aims to develop strategies to block KRAS protein function and improve treatment outcomes.
A study of 582 patients with stage I non-small cell lung cancer (NSCLC) found SBRT to be safe and effective, with a three-year freedom from local progression rate of 79.6%. The biological effective dosage was the most significant factor influencing outcomes.
A recent study found that lung cancer in women who have never smoked is more frequently associated with EGFR mutations and estrogen receptor (ER) overexpression. The researchers observed a higher percentage of these genetic abnormalities in patients who had not previously smoked, suggesting potential new treatment targets for this group.
Researchers evaluate immunohistochemistry for detecting ALK rearrangement in lung adenocarcinoma, finding it a reliable and cost-effective method. The study suggests that IHC can effectively detect ALK rearrangement and identify suitable candidates for targeted therapy.
Researchers at UT Dallas discovered that lung cancer cells consume more oxygen and synthesize a critical chemical called heme, which can be exploited to inhibit cancer growth. Inhibiting heme synthesis affects lung cancer cells' ability to proliferate and migrate.
A study by St. Jude Children's Research Hospital found that 98% of childhood cancer survivors have at least one chronic health condition, with 80% developing a life-threatening condition by age 45. Regular medical checkups and healthy lifestyle choices can help mitigate risk.
Dr. Matt Huentelman and Dr. Glen Weiss are among the 40 Under 40 honorees recognized by the Phoenix Business Journal for their contributions to genomic research, including TGen's MindCrowd project and lung cancer studies. The recognition highlights the institute's advancements in understanding human genetics and developing new treatments.
Researchers have discovered a new oncogene, NTRK1, that drives a subset of lung cancers. A novel targeted treatment approach has been proposed, with preclinical studies showing effective silencing of mutated NTRK1 genes using specific compounds.
Researchers have discovered a new oncogene, RET rearrangement, which is present in 15.7% of lung adenocarcinoma patients and may be targeted with existing tyrosine-kinase inhibitors. This finding presents a promising treatment option for patients with this specific mutation.
Researchers found that crizotinib boosts median disease progression time to 7.7 months, compared to 3 months with standard chemotherapy, in patients with non-small cell lung cancer harboring an abnormal ALK gene.
Two MGH-led studies show crizotinib is superior to chemotherapy for advanced ALK-positive non-small cell lung cancer, with over double the progression-free survival. A second study reports the first crizotinib resistance in a ROS1-positive lung tumor, revealing the mechanism underlying that resistance.
Researchers at Fox Chase Cancer Center are conducting further tests on the drug nivolumab, a monoclonal antibody that targets the immune system's response to cancer. The therapy appears to produce largely manageable side effects and has shown potential in treating tumors more effectively than current treatments.
Sarcomatoid lung carcinomas are rare and aggressive diseases resistant to chemotherapy. Researchers found higher levels of programmed death ligand-1 (PD-L1) in these tumors, which may lead to the use of anti-PD-1/PD-L1 targeted therapies. This discovery supports potential novel immunotherapy approaches for this difficult-to-treat disease.